Three billion shares is going to require a whole lot more then this to move the needle. I think this is headed to sub-penny territory as the management simply over-promised and under-delivered on the news front.

Only announce news when a deal is 100% completely done. Eliminate the thirty sentences of adjectives, and focus on creating shareholder value.
Hmmm....such a novel concept. Do that right, and you have all the funding in the world for expansion and partnerships instead of selling equity for fraction of a cent.

Steve Jobs was fired from Apple, and the company nearly died. He was brought back and then everything turned around. The execution by the management is key in any company. No doubt the prior CEO did not execute - and this one has already proven it's different this time. Real revenue! Significant revenue, and significant partners. If you do not see or understand that - then you should exit your position.

I think they will. But I would like them to hire a professional PR/Investor Relations firm that can craft news releases that are professional and factual - and I do not know actually announce news. They seriously need advisement in that regard. I firmly believe they have the goods - but their PR/Investor Relations could certainly be better.

If you want to look back, no question the prior management was sloppy and had poor execution. It's a changed company "clearly" with what looks like approx. $20 million in revenue. When enough people realize these successes the stock will jump big time. If they in fact landed a deal with Bayer - then it demonstrates that they can actively compete and operate with the best of them. If they can do that - then I think they will do many other deals that build on revenue.

Plain and simple - they made a deal; They pledged their stock and cash to secure the rights, and they are working with a distributor (BV Medica which they co-own to get their products to market. The new CEO took the right steps, and several other deals are either done or in various of completion. They are having some significant success with a decent sized re-order on their female pharma product Gynofit.

Every deal takes more time then anyone can imagine, and as more bare fruit the stock will appreciate.

If you want to look hard enough - you can find something wrong with every company on the planet. If you in essence own a drug or territory - then you largely call the shots. It does not matter what size the company is - it's just the way it works.

In some markets - it's not just the value a a specific product - but a category. If you sell female health products, and this is a missing category - then Bayer would be interested.

I have seen this exact scenario with many pharma firms. I am not saying a deal is done, who knows. but bayer looks like the most likely candidate. If that is true - then easton is not only the real deal - but a shrewd new player in the market. If all of their initiatives take root, and they even come close to generating this kind of revenue - then the sky in truly the limit.

It appears a large block of shares traded at/after the close at .03 yesterday. Looked pretty close to me.

I have read several articles from these guys, whom favor a few stocks and then seem to bad mouth the bunch months later.

What I have also read and or experienced is massive shortages in Las Vegas - as demand has out-stripped the most hyped number ten fold. That Colorado books $100 million in sales per month and growing - and California and Canada to be coming online early next year.

This is a boom, far bigger then the Internet boom - and dare I say it - with a product that is selling like crazy - not just some name with a dot com at the end of it. Yes, no single company is going to enjoy all the profits - and that's not a bad thing. The industry requires and needs many players for both revenue - and to be able to properly play the politics game. The industry money is becoming massive, and as we all know - money is what makes the world go around. Be prepared for the sector to explode - and trust me when I say this - this is only the very begining.

New 52 Week high looks like it's in the cards this week!

Let's see if the chart can paint a close above .035. If so, next testing ground would be about .045! I think we have a good shot in taking out the old high of .06 by the end of the week!

Easton currently distributes MMJ (Gynofit) which is a MMJ based and in itself classifies them a MMJ company. In addition they clearly have their sites on becoming a grower, distributor, and a vape supplier of products which will include I am sure flavored MMJ products in the future. Not to mention other products.

A strong move above .219 and multiple days above that line - would confirm and solidify a new run on the stock. The consolidation of the stock, I am sure shock loose the weaker hands and a meaningful move looks very likely. Once we close above .06 - .065 expect a run into the teens.

Looks like a very green week indeed! Go EAPH!

Your assumptions are really based upon the past, not the present, and not the future. Clearly there is a big difference this time around and the stock price is going to rally very hard. The shake-out is done - now the real rally begins!

Expect the high teens in just a few short weeks!

.18 in less than six weeks out!

New Highs to be made over the next six weeks. The news is real, the profits are real, and patience prevails. I predicted a major shake-out of weaker hands to stronger ones, and for those day traders - it's been a blood bath. Now watch this take out the old high - and by a significant margin - more then triple. Doomsday folks, get ready to eat your words.

Testing a break-out at .256 or better yet .26 - we then have the capacity of re-testing the old high. After we push through that, I see the mid to upper teens as the next major resistance point. (.16-.19)

We could easily see the .45-.60 with the Bayer deal some of the other initiatives! Loving it!

I see EAPH investment in AMFE - as an organic producer utilizing Grozone being of great interest to Bayer. A very unique spin on things! Interesting stuff ....either way it's headed to the moon.

If only stock charts were ever right. Almost every buy or sell signal they have ever issued for EAPH has been wrong within a day or so. Unless there is a huge move - I would not take any signal they give with any credence.

5...4...3...2...1 - We have lift off! EAPH is on it's maiden voyage to new highs!

New Instatutional Beneficial Ownership: Vantage Investment Advisors, LLC
700,000 shares Reported: Dec 30, 2016 Recently updated on Yahoo Profile page

Major gap open - coming soon! I am calling it now - so when it hits - you know who predicted it.
You guessed it - major news coming shortly!

Expect .20+ cents shortly with news on new strategic partners! Get ready for a quick sprint to the low 20's!

Expect teens in May and 20's in June. Grossly under-valued and over-sold! Big stock moving news events will be delivered shortly.

This stock will definitely move up into the teens this month, and higher in June. You can bet the ranh on it. Big things are coming!

You have some disappointed long term holders - and a profit is a profit - even at .03 cents. But it's foolish to sell at these levels - as were building a base at roughly .03 cents. Next level to test 7.5 cents.
Then into the teens!

Silly Willy - keep dreaming!

Dreaming at .01! / Maybe .10 is more likey.

I think you mis-understand dilution. If you have shares that are part of the float - and there is no revenue associated with those shares - then the shares have little or no value. If you add additional shares as part of the over-all float (but revenue comes with the issuance of those shares) then it's not technically dilutive.

EAPH IS CLOSING & DELIVERING


EAPH / Herbs of Kedem - $2,000,000 in Revenue
EAPH / AMFE (Stock Trading at .09) Investment Ownership - RUp-listing in June
EAPH / iBLISS ACQUISITION – Acquisition Complete - $15,000,000 in Revenue
EAPH / GEDEON RICHTER BIG PHARMA JV – Gynofit - Est, $2.5 - $5,000,000 in Revenue
EAPH / BAYER BIG PHARMA JV – Al-Sense Est. $3,5 -$7,000,000 - Pending
EAPH / Assorted Misc Generic Cancer Drugs (36 total) in various states of approval
EAPH / JAMACIA MMJ JV – MMJ producer JV pending with MMJ

Bayer - another huge deal almost done! The recent sellers are going to regret those sells, hang tight folks .075 is the first target, .095 is next, then teens!

Next three news announcements will push this into the teens!

This is headed to $1.00! Almost all of the future deals look to be pegged in the tens of millions of dollars in revenue. Add them up - and this bad boy is going to take off.

The rumor mill was circulating that EAPH deleted a tweet on Friday. If you dig deep in Google archives - it appears the tweet was about Bayer - and then was deleted. You can catch the first part of the sentence.

This is headed to 7.5 cents in short order, and then .015 in early May. many more deals to be announced.

Major news coming shortly! Another acquisition!

Watch a push above.035 tomorrow! That will trigger a technical "buy" that has been weeks in the making with or without news. We will then test new highs, and with "news" to follow we should begin testing the double digits for the first time.

Look for mid-teens my the end of the month. May in the 20's, /June 30's to 40's /$1+ Year end.

Easton #EAPH Have A Positive Update On Closed Agreement To Announce Which Is Anticipated By Early Next Week. Easton Cash Are Making Results

This stock is headed higher and once it goes, there will be no looking back!